Evaluation of the genotoxic potential of three phenyltetrahydropyridinyl butylazole-derived sigma-receptor ligand drug candidates

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 653, Issue 1-2, 2008, Pages 91-98

  Guzmán, Antonio ^a,b   García, Concepción ^a   Marín, Ana Paz ^a   Proudlock, Raymond J ^c   Henestrosa, Antonio R Fernández de ^a   Ruiz, Maria Teresa ^a   Tortajada, Araceli ^a   Lloyd, Mel ^d   Marcos, Ricard ^b  

^a ESTEVE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HUNTINGDON LIFE SCIENCES   (United Kingdom)

^d UK   (United Kingdom)

Author keywords

Genotoxicity; Hypothermia; Phenyltetrahydropyridinyl butylazole; Sigma receptor

Indexed keywords

4 (4 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 [4 (1,2,4 TRIAZOL 1 YL)BUTYL]PYRIDINE; PYRROLE DERIVATIVE; SIGMA RECEPTOR LIGAND; FUSED HETEROCYCLIC RINGS; LIGAND; NEUROLEPTIC AGENT; POLYCYCLIC AROMATIC HYDROCARBON; PYRIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; TRIAZOLE DERIVATIVE;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BODY TEMPERATURE; BONE MARROW; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ERYTHROCYTE; FEMALE; GENETIC TOXICOLOGY; GENOTOXICITY; HYPOTHERMIA; IN VITRO STUDY; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC ACTIVATION; MICRONUCLEUS; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK; SAMPLING; SOLUBILITY; ANIMAL; BONE MARROW CELL; CHEMISTRY; DRUG POTENTIATION; DRUG SCREENING; ERYTHROBLAST; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; TIME; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BONE MARROW CELLS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ERYTHROBLASTS; HETEROCYCLIC COMPOUNDS, 3-RING; LIGANDS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MICE; MICRONUCLEUS TESTS; POLYCYCLIC HYDROCARBONS, AROMATIC; PYRIDINES; RECEPTORS, SIGMA; TIME FACTORS; TRIAZOLES;

EID: 49649128680     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.03.011     Document Type: Article

References (45)

1. Corbera J., Vaño D., Martinez D., Vela J.M., Zamanillo D., Dordal A., Andreu F., Hernandez E., Perez R., Escriche M., Salgado L., Yeste S., Serafini M.T., Pascual R., Alegre J., Calver M.C., Cano N., Carro M., Buschmann H., and Holenz J. A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligands. ChemMedChem 1 (2006) 140-154
2. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
3. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., and Taylor D.P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 13 (1992) 85-86
4. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., and Bowen W.D. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268 (1994) 9-18
5. Crawford K.W., and Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62 (2002) 313-322
6. ICH, Topic S2A Genotoxicity: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Approved September 1995.
7. ICH, Topic S2B, Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Step 4 Guideline, 16 July 1997.
8. Guzman A., Garcia C., de Henestrosa A.R., Riley S., Ruiz M.T., Marin A.P., and Tortajada A. Assessment of the genotoxic potential of the antipsychotic sigma receptor ligand E-5842. Mutat. Res. 605 (2006) 63-77
9. Maron D.M., and Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113 (1983) 173-215
10. Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals, No. 471. Genetic Toxicology: Bacterial Reverse Mutation Test (1997)
11. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50 (1955) 1096-1121
12. Student. The probable error of a mean. Biometrika 6 (1908) 1-25
13. Cole J., Mc Gregor D.B., Fox M., Graner R.C., and Thacker J. Gene mutation assay in cultured mammalian cells. In: Kirkland D.J. (Ed). Basic Mutagenicity Tests UKEMS Recommended Procedures (1990), Cambrige University Press 87-114
14. Organization for Economic Co-operation and Development (OECD). OECD guideline for the testing of chemicals, No. 476. Genetic Toxicology: In vitro mammalian cell gene mutation test (1997)
15. Robinson W.D., Green M.H.L., Cole J., Garner R.C., Healy M.J.R., and Gatehouse D.G. Statistical evaluation of bacteria/mammalian fluctuation test. In: Kirkland D.J. (Ed). Statistical Evaluation of Mutagenicity Test Data (1990), Cambrige University Press 102-140
16. Schmid W. The micronucleus test. Mutat. Res. 31 (1975) 9-15
17. Organization for Economic Co-operation and Development (OECD). OECD guideline for the testing of chemicals, No. 474. Genetic Toxicology: Mammalian Erythrocyte Micronucleus Test (1997)
18. EEC, Council Directive 86/609/EEC, 24 November 1986.
19. Fielder R.J., Allen J.A., Boobis A.R., Botham P.A., Doe J., Esdaile D.J., Gatehouse D.G., Hodson-Walker G., Morton D.B., and Kirkland D.J. Report of British Toxicology Society/UK Environmental Mutagen Society Working Group. Dose setting in in vivo mutagenicity assays. Mutagenesis 7 (1992) 313-319
20. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use, 28 June 2006, Guideline on the limits of genotoxic impurities.
21. Moore M.M., Honma M., Clements J., Bolcsfoldi G., Burlinson B., Cifone M., Clarke J., Delongchamp R., Durward R., Fellows M., Gollapudi B., Hou S., Jenkinson P., Lloyd M., Majeska J., Myhr B., O'Donovan M., Omori T., Riach C., San R., Stankowski Jr. L.F., Thakur A.K., Van Goethem F., Wakuri S., and Yoshimura I. Mouse lymphoma thymidine kinase gene mutation assay: follow-up meeting of the International Workshop on Genotoxicity Testing--Aberdeen, Scotland, 2003--Assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen. 47 (2006) 1-5
22. Krishna G., Urda G., and Paulissen J. Historical vehicle and positive control micronucleus data in mice and rats. Mutat. Res. 453 (2000) 45-50
23. Salamone M.F., and Mavournin K.H. Bone marrow micronucleus assay: a review of the mouse stocks used and their published mean spontaneous micronucleus frequencies. Environ. Mol. Mutagen. 23 (1994) 239-273
24. Guzman A., Garcia C., Marin A.P., Ruiz M.T., Tortajada A., and Fernandez de Henestrosa A.R. Induction of micronuclei in mouse bone-marrow erythrocytes in association with hypothermia after administration of the sigma receptor ligand E-5842. Mutat. Res. 565 (2004) 11-22
25. Asanami S., and Shimono K. Hypothermia induces micronuclei in mouse bone marrow cells. Mutat. Res. 393 (1997) 91-98
26. Asanami S., Shimono K., and Kaneda S. Transient hypothermia induces micronuclei in mice. Mutat. Res. 413 (1998) 7-14
27. Tweats D.J., Blakey D., Heflich R.H., Jacobs A., Jacobsen S.D., Morita T., Nohmi T., O'donovan M.R., Sasaki Y.F., Sofuni T., and Tice R. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutat. Res. 627 (2007) 78-91
28. Suzuki Y., Nagae Y., Ishikawa T., Watanabe Y., Nagashima T., Matsukubo K., and Shimizu H. Effect of erythropoietin on the micronucleus test. Environ. Mol. Mutagen. 13 (1989) 314-318
29. Kirkland D. Selection of mutagenicity and cell transformation tests-interpretation of results. Preclinical Evaluation of Peptides and Recombinant Proteins (1991), Association of the Swedish Pharmaceutical industry and the Swedish National board of Health and Welfare pp. 49-56
30. Suzuki Y., Shimizu H., Nagae Y., Fukumoto M., Okonogi H., and Kadokura M. Micronucleus test and erythropoiesis: effect of cobalt on the induction of micronuclei by mutagens. Environ. Mol. Mutagen. 22 (1993) 101-106
31. Yajima N., Kurata Y., Sawai T., and Takeshita Y. Induction of micronucleated erythrocytes by recombinant human erythropoietin. Mutagenesis 8 (1993) 221-229
32. Snyder R.D., and Diehl M.S. Hypoxia-induced micronucleus formation in mice. Drug Chem. Toxicol. 28 (2005) 373-378
33. Spencer P.J., Gollapudi B.B., and Waechter Jr. J.M. Induction of micronuclei by phenol in the mouse bone marrow: I. Association with chemically induced hypothermia. Toxicol. Sci. 97 (2007) 120-127
34. Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol. Toxicol. 84 (1999) 193-196
35. Cryan J.F., Kelliher P., Kelly J.P., and Leonard B.E. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J. Psychopharmacol. 13 (1999) 278-283
36. Cryan J.F., Harkin A., Naughton M., Kelly J.P., and Leonard B.E. Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action. Eur. J. Pharmacol. 390 (2000) 275-285
37. Oerther S. Temperature set-point changes induced by DA D2/3 and 5-HT1A receptor agonists in the rat. Neuroreport 11 (2000) 3949-3951
38. Oerther S., and Ahlenius S. Involvement of 5-HT1A and 5-HT1B receptors for citalopram-induced hypothermia in the rat. Psychopharmacology (Berl.) 154 (2001) 429-434
39. Perachon S., Betancur C., Pilon C., Rostene W., Schwartz J.C., and Sokoloff P. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport 11 (2000) 221-225
40. Bejanian M., Pechnick R.N., Bova M.P., and George R. Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-Di-o-tolylguanidine on body temperature in the rat: interactions with BMY 14802 and rimcazole. J. Pharmacol. Exp. Ther. 258 (1991) 88-93
41. Kest B., Mogil J.S., Sternberg W.F., Pechnick R.N., and Liebeskind J.C. Antinociception following 1,3,-di-o-tolylguanidine, a selective sigma receptor ligand. Pharmacol. Biochem. Behav. 50 (1995) 587-592
42. Rawls S.M., Baron D.A., Geller E.B., and Adler M.W. Sigma sites mediate DTG-evoked hypothermia in rats. Pharmacol. Biochem. Behav. 73 (2002) 779-786
43. Largent B.L., Gundlach A.L., and Snyder S.H. Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharmacol. Exp. Ther. 238 (1986) 739-748
44. Bouchard P., and Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 76 (1997) 467-477
45. Guitart X., Codony X., Ballarin M., Dordal A., and Farre A.J. E-5842: a new potent and preferential sigma ligand. Preclinical pharmacological profile, CNS. Drug. Rev. 4 (1998) 201-224